» Articles » PMID: 38232993

Development of a Cross-sectoral Antimicrobial Resistance Capability Assessment Framework

Abstract

Antimicrobial resistance (AMR) is an urgent and growing global health concern, and a clear understanding of existing capacities to address AMR, particularly in low-income and middle-income countries (LMICs), is needed to inform national priorities, investment targets and development activities. Across LMICs, there are limited data regarding existing mechanisms to address AMR, including national AMR policies, current infection prevention and antimicrobial prescribing practices, antimicrobial use in animals, and microbiological testing capacity for AMR. Despite the development of numerous individual tools designed to inform policy formulation and implementation or surveillance interventions to address AMR, there is an unmet need for easy-to-use instruments that together provide a detailed overview of AMR policy, practice and capacity. This paper describes the development of a framework comprising five assessment tools which provide a detailed assessment of country capacity to address AMR within both the human and animal health sectors. The framework is flexible to meet the needs of implementers, as tools can be used separately to assess the capacity of individual institutions or as a whole to align priority-setting and capacity-building with AMR National Action Plans (NAPs) or national policies. Development of the tools was conducted by a multidisciplinary team across three phases: (1) review of existing tools; (2) adaptation of existing tools; and (3) piloting, refinement and finalisation. The framework may be best used by projects which aim to build capacity and foster cross-sectoral collaborations towards the surveillance of AMR, and by LMICs wishing to conduct their own assessments to better understand capacity and capabilities to inform future investments or the implementation of NAPs for AMR.

Citing Articles

Establishing carbapenem resistant organism surveillance, prevention, and control in a middle-income country: implementation of a hospital-based program in Fiji.

Getahun Strobel A, Kumar S, Prasad S, Young-Sharma T, Richards M, Datt A Antimicrob Resist Infect Control. 2025; 14(1):19.

PMID: 40038841 PMC: 11881281. DOI: 10.1186/s13756-025-01534-5.


Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings.

Mishra S, Akter T, Urmi U, Enninful G, Sara M, Shen J Antibiotics (Basel). 2025; 14(1).

PMID: 39858343 PMC: 11762091. DOI: 10.3390/antibiotics14010057.


A Situation Analysis of the Capacity of Laboratories in Faith-Based Hospitals in Zambia to Conduct Surveillance of Antimicrobial Resistance: Opportunities to Improve Diagnostic Stewardship.

Shempela D, Mudenda S, Kasanga M, Daka V, Kangongwe M, Kamayani M Microorganisms. 2024; 12(8).

PMID: 39203539 PMC: 11357258. DOI: 10.3390/microorganisms12081697.

References
1.
Nielsen L, Alban L, Ellis-Iversen J, Mintiens K, Sandberg M . Evaluating integrated surveillance of antimicrobial resistance: experiences from use of three evaluation tools. Clin Microbiol Infect. 2020; 26(12):1606-1611. DOI: 10.1016/j.cmi.2020.03.015. View

2.
Loftus M, Curtis S, Naidu R, Cheng A, Jenney A, Mitchell B . Prevalence of healthcare-associated infections and antimicrobial use among inpatients in a tertiary hospital in Fiji: a point prevalence survey. Antimicrob Resist Infect Control. 2020; 9(1):146. PMC: 7456377. DOI: 10.1186/s13756-020-00807-5. View

3.
Abraao L, Nogueira-Junior C, Orlandi G, Zimmerman P, Padoveze M . Infection prevention and control program assessment tools: A comparative study. Am J Infect Control. 2022; 50(10):1162-1170. DOI: 10.1016/j.ajic.2022.01.020. View

4.
Pokharel S, Raut S, Adhikari B . Tackling antimicrobial resistance in low-income and middle-income countries. BMJ Glob Health. 2019; 4(6):e002104. PMC: 6861125. DOI: 10.1136/bmjgh-2019-002104. View

5.
de Kraker M, Stewardson A, Harbarth S . Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?. PLoS Med. 2016; 13(11):e1002184. PMC: 5127510. DOI: 10.1371/journal.pmed.1002184. View